Japan CreditStats 2011: Continued Improvement In Financial Standing In Fiscal 2010 Underpinned Swift Recovery From Quake Dec 11

  • ID: 2034931
  • December 2011
  • Region: Japan
  • Standard & Poors
1 of 2

The financial strength of Japanese companies improved for the second consecutive year in fiscal 2010 (ended March 31, 2011, for most companies; Dec. 31, 2010, and other days for some companies), according to an annual survey Standard & Poor's Ratings Services has compiled. The survey finds that an increasing number of companies further accumulated cash on hand amid wariness about the direction of the domestic economy, in Standard & Poor's view, following the Great East Japan Earthquake on March 11, 2011. The survey covered 226 companies, comprising 53 Japanese companies rated by Standard & Poor's and 173 unrated companies that are component parts of the S&P/TOPIX150 or S&P Japan Mid Cap 100--both subindices of the S&P Japan 500, one of...

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.